ST-162

N/A

Report date: 2023/01/03 11:45:11

NME

Base Information

Drug NameST-162

Drug Alias NameST-162

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionDual specificity mitogen-activated protein kinase kinase 1 inhibitorsPhosphatidylinositol 3 kinase alpha inhibitorsPhosphatidylinositol 3 kinase beta inhibitors +[5]

TargetsDual specificity mitogen-activated protein kinase kinase 1Phosphatidylinositol 3 kinase alphaPhosphatidylinositol 3 kinase beta +[5]

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Michigan

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Michigan

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A